En Es

Industry News

DIAsource Immunoassays Enters Agreement with ZenTech for RIA Products

By Labmedica International staff writers
31 Jul 2018

Image: DIAsource Immunoassays has entered into an agreement with ZenTech for its portfolio of radioimmunoassays (RIA) products (Photo courtesy of iStock).DIAsource Immunoassays (Brabant Wallon, Belgium), a BioVendor group company, has entered into a strategic agreement with ZenTech (Angleur, Belgium) under which ZenTech will transfer its portfolio of radioimmunoassays (RIA) products to DIAsource, securing their continued production and sales.

DIAsource ImmunoAssays is a diagnostics company specialized in the development, manufacturing, and sales and distribution of immunoassay tests and open instrumentation solutions for clinical diagnostics. It delivers manual RIA and ELISA kits and open automation solutions to the international markets, and has a portfolio of over 190 ELISA and 140 RIA assays. ZenTech specializes in the development, production and commercialization of solutions for clinical diagnostics of early life stage diseases and newborn screening. It has a broad portfolio of products in prenatal, neonatal and pediatric screening and offers complete and flexible solutions to set up the screening activity.

Both the companies have long standing collaborations for more than 15 years, with DIAsource already successfully managing a part of the commercialization of the ZenTech portfolio. The current transfer of RIA products from ZenTech to DIAsource is in line with their strategies. The portfolio to be transferred includes the complete line of special RIAs with thyroid markers and markers for fertility and salt balance. Effective July 24, 2018, DIAsource Immunoassays has assumed commercial ownership of ZenTech’s RIA product portfolio and will service clients from order to shipment, while ZenTech will remain the manufacturer during the transition period in which the production will be transferred to DIAsource. The transfer of production will be done in close collaboration and in phases to be concluded by September 30, 2019.

“Historically, ZenTech had a background and expertise in radioimmunoassays. However, when ZenTech acquired the Belgian company Gamma in 2011, it got access to new technologies and entered the market of newborn screening and early life stage diseases,” said Jean-Claude Havaux, Chairman of the Board, ZenTech. “Today's acquisition of the RIA products by ZenTech’s commercial partner DIAsource will guarantee RIA customers are offered long-term service and excellence in logistics worldwide. This transaction will give ZenTech the opportunity to focus on new innovative product lines and other technologies such as molecular diagnostics and mass spectrometry.”

“This acquisition is yet another step in our strategy to position DIAsource as a consolidator of manual specialty assays, after previous acquisitions of the Intertech RIA product line in 2012 and Viro-Immun ELISA and IFA product lines in 2017. DIAsource also acquired the RIA client businesses from distribution partners in France and Spain in 2015 and 2016. This fourth acquisition in the RIA space demonstrates our commitment to the long term future servicing and support of our large RIA customer base worldwide,” said Jef Vangenechten, CEO of DIAsource Immunoassays. “We experience that RIA remains important as the gold standard for assays that are not available on automated systems or for parameters that require a higher analytical accuracy, whereby manual assays offer benefits in terms of quality and flexibility versus price. DIAsource now has a unique position by combining the most complete offering of RIA specialty assays on the market with the ability to offer various RIA automation solutions. Furthermore our manual assays also allow customization for life science research and screening,” added Vangenechten.

E-mail Print
FaceBook Twitter Google+ Linked in


Develops, manufactures, and markets clinical diagnostic products that focus on endocrinology and infectious diseases
Gold member
More info

More articles about DIASOURCE

19 Sep 2017
DIAsource ImmunoAssays SA Acquires Viro-Immun Diagnostics
DIAsource ImmunoAssays SA, which develops, sells and distributes clinical diagnostics products, has acquired Viro-Immun Diagnostics GmbH, a developer and manufacturer of laboratory diagnostics for the medical diagnosis of infectious and autoimmune diseases.
Read More

Additional news

21 Mar 2019
Baxter and bioMérieux in Alliance to Develop Acute Kidney Injury Diagnostics
Baxter International Inc. and bioMérieux announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI).
Read More
19 Mar 2019
Advantech Launches All-in-One Computer for Healthcare Applications
Advantech, a provider of medical computing systems, has launched its POC-L series of non-medical-grade point-of-care touch computers comprising two models differentiated according to their display size – POC-W213L (21.5 inches) and POC-W243L (23.8 inches).
Read More
19 Mar 2019
AI Algorithm Identifies Lung Tumors Faster Than Other Methods
Computing scientists at the University of Alberta have developed a neural network that outperforms other state-of-the-art methods of identifying lung tumors from MRI scans—creating the potential to help reduce damage to healthy tissue during radiation treatment.
Read More
19 Mar 2019
Machine Learning Method Can Help Women Avoid Unnecessary Breast Surgery
A team of researchers from the Geisel School of Medicine at Dartmouth has developed a machine learning method to predict atypical ductal hyperplasia (ADH) upgrade to cancer.
Read More
19 Mar 2019
First AI-Based Tool for Pulmonary Embolism Receives CE Certification
Aidoc, a provider of artificial intelligence (AI) solutions for radiologists, has announced the commercial release of its CE-marked product for the identification and triage of pulmonary embolism (PE) in CT pulmonary angiograms.
Read More
19 Mar 2019
World’s First AI-Based Algorithms for ED Receive CE Certification
Zebra Medical Vision has received two new CE marked registrations for its deep learning algorithms that help radiologists and Emergency Room (ER) staff to prioritize acute conditions for the first time in both CT scans and X-rays and reduce reports turnaround time (RTAT).
Read More
19 Mar 2019
Global Neonatal Ventilator Market to Surpass USD 466 Million by 2025
The global neonatal ventilator market is expected to surpass USD 466.1 million by 2025 as rising incidences of preterm births with respiratory disorders and mortality rates will drive the demand for various neonatal ventilators worldwide.
Read More
11 Mar 2019
Carestream Health to Sell Healthcare IT Business to Philips
Carestream Health has entered into an agreement with Royal Philips to sell its healthcare information systems (HCIS) business to Philips.
Read More
07 Mar 2019
Investments in AI Imaging Start-ups Increased to USD 580 Million in 2018
Capital investments in start-up companies developing medical imaging artificial intelligence (AI) solutions more than doubled to USD 580 million in 2018 from USD 270 million in 2017.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions